Immunoprecise Stock Story

IPA -  USA Stock  

USD 6.30  0.10  1.61%

As many investors are getting excited about healthcare space, Immunoprecise Antibodies and Mustang Bio may be going in opposite directions. We are going to analyze some of the competitive aspects of both Immunoprecise and Mustang.
Published over a month ago
View all stories for Immunoprecise Antibodies | View All Stories
Will Immunoprecise Antibodies (NASDAQ:IPA) investors shift to Mustang (NASDAQ:MBIO)?
By analyzing existing basic indicators between Immunoprecise Antibodies and Mustang, you can compare the effects of market volatilities on both companies' prices and check if they can diversify away market risk if combined in one of your portfolios. You can also utilize pair trading strategies for matching a long position in Mustang with a short position in Immunoprecise Antibodies. Check out our pair correlation module for more information.

Let's begin by analyzing the assets.
One of the ways to look at asset utilization of Immunoprecise is to check how much profit was generated for every dollar of assets it reports. Immunoprecise Antibodies retains a negative application of resources of -9.67 (percent), losing $0.0967 for each dollar of resources held by the firm. Inadequate asset utilization attests that the company is being less effective with each dollar of resources it retains. Simply put, asset utilization of Immunoprecise Antibodies shows how discouraging it operates for each dollar spent on its resources.

How important is Immunoprecise Antibodies's Liquidity

Immunoprecise Antibodies financial leverage refers to using borrowed capital as a funding source to finance Immunoprecise Antibodies ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Immunoprecise Antibodies financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Immunoprecise Antibodies's total debt and its cash.

How does Immunoprecise utilize its cash?

To perform a cash flow analysis of Immunoprecise Antibodies, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Immunoprecise Antibodies is receiving and how much cash it distributes out in a given period. The Immunoprecise Antibodies cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Immunoprecise Antibodies Net Cash Flow from Operations is projected to increase significantly based on the last few years of reporting. The past year's Net Cash Flow from Operations was at (690,000)

Going after Immunoprecise Financials

Cash and Equivalents Breakdown

Now, let's check Immunoprecise Antibodies cash and equivalents. In accordance with the recently published financial statements, Immunoprecise Antibodies has 15.72 M in Cash and Equivalents. This is 98.08% lower than that of the Healthcare sector and 96.48% lower than that of the Biotechnology industry. The cash and equivalents for all United States stocks is 99.42% higher than that of the company. As for Mustang Bio we see cash and equivalents of 129.92 M, which is 70.94% lower than that of the Biotechnology

Sector
447.1 M
MBIO
129.9 M
IPA15.72 Million2.65
Sector447.12 Million75.43
MBIO129.92 Million21.92

Our perspective of the current Immunoprecise Antibodies rise

Current Information Ratio is up to -0.09. Price may slip again. Immunoprecise Antibodies exhibits very low volatility with skewness of 0.45 and kurtosis of 0.3. However, we advise investors to further study Immunoprecise Antibodies technical indicators to make sure all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Immunoprecise Antibodies' stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Immunoprecise Antibodies' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Immunoprecise Antibodies Implied Volatility

Immunoprecise Antibodies' implied volatility exposes the market's sentiment of Immunoprecise Antibodies stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Immunoprecise Antibodies' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Immunoprecise Antibodies stock will not fluctuate a lot when Immunoprecise Antibodies' options are near their expiration.

The Current Takeaway on Immunoprecise Antibodies Investment

Whereas many of the other players under the biotechnology industry are still a bit expensive, Immunoprecise Antibodies may offer a potential longer-term growth to investors. While some investors may not share our view we believe that the current risk-reward utility is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Immunoprecise Antibodies.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of Immunoprecise Antibodies. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com